Descripción

Clinical trial outcomes for berberine supplementation in human NAFLD patients are summarized, showing trends toward improved liver function tests and hepatic fat content reduction in treated versus placebo groups.

Figure 27

Chart

Source Paper

Berberine Effects in Pre-Fibrotic Stages of Non-Alcoholic Fatty Liver Disease-Clinical and Pre-Clinical Overview and Systematic Review of the Literature.

International journal of molecular sciences (2024)

PMID: 38673787

DOI: 10.3390/ijms25084201

Cite This Figure

![Figure 27: Clinical trial outcomes for berberine supplementation in human NAFLD patients are summarized, showing trends toward improved liver function tests and hepatic fat content reduction in treated versus placebo groups.]()

> Source: Florentina Ionita-Radu et al. "Berberine Effects in Pre-Fibrotic Stages of Non-Alcoholic Fatty Liver Disease-Cl." *International journal of molecular sciences*, 2024. PMID: [38673787](https://pubmed.ncbi.nlm.nih.gov/38673787/)

<figure>
  <img src="" alt="Clinical trial outcomes for berberine supplementation in human NAFLD patients are summarized, showing trends toward improved liver function tests and hepatic fat content reduction in treated versus placebo groups." />
  <figcaption>Figure 27. Clinical trial outcomes for berberine supplementation in human NAFLD patients are summarized, showing trends toward improved liver function tests and hepatic fat content reduction in treated versus placebo groups.<br>  Source: Florentina Ionita-Radu et al. "Berberine Effects in Pre-Fibrotic Stages of Non-Alcoholic Fatty Liver Disease-Cl." <em>International journal of molecular sciences</em>, 2024. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/38673787/">38673787</a></figcaption>
</figure>

Evidencia relacionada

Berberine para Gut Dysbiosis

Calificación D · 2 estudios